BioMarin Pharmaceutical Inc. (BMRN)

Environment story

BioMarin has not disclosed Scope 1, 2, or 3 emissions data, net-zero targets, or renewable energy commitments in the provided 10-K filing. The company operates manufacturing and laboratory facilities with a significant on-site workforce (1,518 employees in operations), suggesting material operational energy consumption, but no environmental reporting, sustainability initiatives, or climate commitments are documented in the available source material. Without disclosed emissions baselines, targets, or decarbonization infrastructure investments, the environmental pillar defaults to baseline with deductions for opacity. No greenwashing indicators are evident because no environmental claims are made.

Social story

BioMarin discloses 3,221 total employees globally as of December 31, 2025, with 2,026 in the U.S. and Canada and 1,195 outside North America. The company states commitment to workplace culture, diversity, professional development, competitive compensation, and benefits. However, the 10-K provides no specific data on CEO-to-median-worker pay ratio, workforce gender or racial diversity percentages, executive leadership diversity, turnover rates, union standing, plant safety metrics, or documented supply-chain labor audits. No labor disputes, NLRB complaints, or union-suppression allegations are disclosed. The company references leveraging 'collective genius of its global workforce' and recruiting from 'broad range of backgrounds' but does not quantify diversity outcomes. Supply-chain ethics for manufacturing inputs (e.g., container materials, raw reagents for enzyme therapies) are not addressed.

Governance story

BioMarin's governance structure and practices are not fully disclosed in the provided 10-K excerpt. No information on board independence percentage, board composition, share structure (single or dual-class), or lobbying expenditures is provided in the extracted text. The company discloses extensive regulatory compliance obligations (FDA, EMA, Medicaid, Medicare, FCPA, anti-kickback statutes, HIPAA, state privacy laws) and notes compliance is 'difficult and time consuming,' but reports no active violations, fines, consent decrees, antitrust proceedings, or privacy enforcement actions as of the filing date. The 10-K extensively discusses government healthcare pricing regulation and reimbursement risk but does not disclose active lobbying against climate or consumer-protection regulation. No shareholder proposals, board elections, or governance votes are detailed in the excerpt.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of BioMarin Pharmaceutical Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open BioMarin Pharmaceutical Inc. in the app for interactive charts and portfolio building.

More in Healthcare